Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is positioning itself at the intersection of artificial intelligence and precision medicine, aiming to transform the early detection and diagnosis of coronary heart disease. The company’s blood-based tests, Epi+Gen CHD and PrecisionCHD, leverage a proprietary AI-driven Multi-Omics Engine that analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss.
The cardiovascular disease market is substantial and growing. According to the company, annual healthcare costs for cardiovascular disease were $393 billion in 2020 and are projected to reach $1.4 trillion by 2050. Cardio Diagnostics addresses this market with tests that can detect coronary heart disease earlier and more accurately than traditional tools. The company’s technology analyzes both genetic and epigenetic markers, providing a comprehensive view of a patient’s risk profile.
Cardio Diagnostics has made significant strides in commercialization. The company has secured finalized CMS reimbursement rates and dedicated CPT laboratory codes, which are critical for widespread adoption by healthcare providers. It has expanded U.S. provider partnerships and launched its first international expansion in India. These milestones indicate that the company’s tests are not only scientifically grounded but also commercially viable.
“Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise,” the company states. The company was formed to further develop and commercialize clinical tests by leveraging its proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, with the goal of becoming a leading medical technology company in this space.
The implications of Cardio Diagnostics’ approach are significant. By detecting coronary heart disease earlier, including forms that are often missed by conventional methods, the company’s tests could help reduce the burden of cardiovascular disease on patients and the healthcare system. The growing adoption by providers and the expansion into international markets like India suggest that the technology is gaining traction. With a proprietary platform, reimbursement milestones, and evidence supporting its ability to detect what traditional tools miss, Cardio Diagnostics occupies a position that is both scientifically grounded and commercially actionable in the diagnostics landscape.
For more information on Cardio Diagnostics, visit https://cdio.ai/. The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.
